Journal list Promote Sponsor
verified SJR 1,448 · Q1 • database Scopus / SJR & Web of Science indexed
Hematology / the Education Program of the American Society of Hematology
United States · American Society of Hematolo...
workspace_premium Q1 — Hematology lock_open Open Access

Hematology / the Education Program of the American Society of Hematology

Hematology / the Education Program of the American Society of Hematology is a journal indexed in SJR in Hematology with an H index of 108. It has a price of 3250 €. It has an SJR impact factor of 1,448 and it has a best quartile of Q1. It is published in English. It has an SJR impact factor of 1,448.

Hematology / the Education Program of the American Society of Hematology focuses its scope in these topics and keywords: young, patients, children, treatment, approach, treated, therapy, patient, natural, history, ...

ISSN: 1520-4391
Publisher: American Society of Hematology
Category: Hematology
Indexation: verifiedScopus / SJR verifiedWeb of Science
open_in_new Portal NPD menu_book Guidelines NPD
schedule CountryOfPapers database fields
SJR Impact Factor trending_up
1,448 Q1
H-index 108
Acceptance rate pie_chart
25% Selective
Source Acceptance_Rate
Time to publication hourglass_top
NPD
Field NPD
Publication cost (APC) payments
3.250 € Open Access
Non-OA path 0 €

Metrics

Scimago and CountryOfPapers database fields

Scopus / SJR Web of Science

SJR Impact

1,448

H-index

108

Docs (year)

102

Docs 3y

288

Total refs

0

Cites 3y

1016

Citable 3y

288

Cites/Doc 2y

3.3

Ref/Doc

0.0

Immediate OA

3250 €

Embargoed OA

NPD

Non OA / Submission

0 €

shield Researcher voice

Name good journals. Call out predatory ones.

Share what peer review, fees, and timelines were really like. Praise fair editors. Flag APC traps, fake metrics, or spam solicitations — with facts from your submission.

Fair & fast peer review Clear APC / no surprise fees Suspected predatory Fake impact claims
rate_review Write an honest review

Researcher reviews

sentiment_dissatisfied No reviews yet — be the first to share an honest experience.
User
* Only to validate authenticity — identity is not shown publicly.

Best articles by citations

Chronic Lymphocytic Leukemia

View more

Which Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Should Be Treated with Eculizumab?

View more

Erythropoietin: A Paradigm for the Development of Practice Guidelines

View more

Duration of Anticoagulation Therapy for Venous Thromboembolism

View more

Does High-Dose Therapy and Autologous Hematopoietic Stem Cell Transplantation Have a Role in the Primary Treatment of Peripheral T-Cell Lymphomas?

View more

Diagnostic and therapeutic challenges in the thrombotic thrombocytopenic purpura and hemolytic uremic syndromes

View more

Current and Future Therapies of Sickle Cell Anemia: An Historical Perspective

View more

Clinically defining and managing high-risk pediatric patients with acute lymphoblastic leukemia

View more

Clinical Challenges in Hodgkin Lymphoma: An Historical Perspective

View more

Chronic Myeloid Leukemia: An Historical Perspective

View more

Chronic Myeloid Leukemia Stem Cells

View more

Chronic Myeloid Leukemia

View more
SHOW MORE ARTICLES

Chronic Lymphocytic Leukemia: An Historical Perspective

View more

A brief, but comprehensive, guide to clonal evolution in aplastic anemia

View more

Childhood and Adolescent Lymphoid and Myeloid Leukemia

View more

Biology and Treatment of Chronic Lymphocytic Leukemia

View more

Anticoagulation in pregnancy complications

View more

Alpha thalassemia major - new mutations, intrauterine management, and outcomes

View more

All transplantation-eligible patients with myeloma should receive ASCT in first response

View more

Advances in Biology and Therapy of Multiple Myeloma

View more

Acute Myeloid Leukemia: The Challenge of Capturing Disease Variety

View more

Acute Myeloid Leukemia; Decided Victories, Disappointments, and Detente: An Historical Perspective

View more

Acute Myeloid Leukemia

View more

Acute Lymphoblastic Leukemia: An Historical Perspective

View more

FAQs